Altimmune (ALT) Competitors

Altimmune (NASDAQ:ALT) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Do insiders & institutionals have more ownership in ALT or INDV?

78.1% of Altimmune shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor ALT or INDV?

Altimmune received 51 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 72.09% of users gave Altimmune an outperform vote.

Company	Underperform	Outperform
Altimmune	Outperform Votes 62 72.09%	Underperform Votes 24 27.91%
Indivior	Outperform Votes 11 100.00%	Underperform Votes No Votes

Do analysts prefer ALT or INDV?

Altimmune currently has a consensus price target of $20.20, indicating a potential upside of 208.87%. Indivior has a consensus price target of $15.00, indicating a potential upside of 9.81%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Which has better valuation & earnings, ALT or INDV?

Indivior has higher revenue and earnings than Altimmune. Indivior is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$20K	26,521.99	-$88.45M	-$1.26	-5.19
Indivior	$1.17B	1.61	$2M	-$0.31	-44.06

Does the media favor ALT or INDV?

In the previous week, Altimmune and Altimmune both had 7 articles in the media. Indivior's average media sentiment score of 1.35 beat Altimmune's score of 1.12 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ALT or INDV more profitable?

Indivior has a net margin of -3.96% compared to Altimmune's net margin of -199,076.92%. Altimmune's return on equity of -55.81% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-199,076.92%	-55.81%	-50.60%
Indivior	-3.96%	-241.73%	15.09%

Which has more volatility and risk, ALT or INDV?

Altimmune has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Summary

Indivior beats Altimmune on 9 of the 17 factors compared between the two stocks.